REGENXBIO Inc. Debt Securities, Available-for-sale, Realized Gain (Loss)
REGENXBIO Inc. (RGNX) reported Debt Securities, Available-for-sale, Realized Gain (Loss) of $0 for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-14.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss · last filed 2026-05-14
- REGENXBIO Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2026-03-31 was $0.00.
- REGENXBIO Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2025-12-31 was $0.00.
- REGENXBIO Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2025-09-30 was $0.00.
- REGENXBIO Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2025-06-30 was $0.00.
- REGENXBIO Inc. debt securities, available-for-sale, realized gain (loss) for fiscal 2025 was $0.00.
- REGENXBIO Inc. debt securities, available-for-sale, realized gain (loss) for fiscal 2024 was $0.00.
- REGENXBIO Inc. debt securities, available-for-sale, realized gain (loss) for fiscal 2018 was -$39.00K, a 108.14% decline from fiscal 2017.
- REGENXBIO Inc. debt securities, available-for-sale, realized gain (loss) for fiscal 2017 was $479.00K.
| Period end | Debt Securities, Available-for-sale, Realized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-03-31 | $0.00 10-Q · filed 2026-05-14 | $0.00 derived: sum of 2 quarters · filed 2026-05-14 | $0.00 derived: sum of 3 quarters · filed 2026-05-14 | $0.00 derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | $0.00 derived: sum of 3 quarters · filed 2026-03-05 | $0.00 10-K · filed 2026-03-05 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $0.00 derived: sum of 3 quarters · filed 2026-05-14 | $0.00 derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-14 | $0.00 derived: sum of 2 quarters · filed 2026-05-14 | $0.00 derived: sum of 3 quarters · filed 2026-05-14 | $0.00 derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | $0.00 derived: sum of 3 quarters · filed 2026-03-05 | $0.00 10-K · filed 2026-03-05 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-12 | |||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-01 | $0.00 10-Q · filed 2024-08-01 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-08 | |||
| 2018-12-31 | -$39.00K 10-K · filed 2019-02-27 | |||
| 2017-12-31 | $479.00K 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |